SRS advises Bionova Capital on investment in Vaxydn
SRS advogados has advised Bionova Capital on its investment in the Spanish startup, Vaxydn, to develop a vaccine against fatal bacteria
SRS Advogados has advised Bionova Capital (ex-Hovione Capital) on its investment in Vaxdyn, a startup company based in Spain and operating in the area of biotechnology. The investment is to fund the development of vaccines against potentially fatal bacteria.
In this funding round, Vaxdyn raised €7.6 million from various investors, with the aim of developing a new vaccine to combat the global crisis of superbugs, namely those that cause pneumonia. Bionova Capital is a leading investor in life sciences and biomedical start-ups in the Portuguese market, investing in molecules and medical devices.
The team from SRS Advogados was led by partner Paulo Bandeira (pictured left) and associate Giorgio Galli (pictured right).
“This advisory service stands out due to the complexity of combining different financing instruments in the transaction and the need to acculturate the practice of venture capital investment by Portuguese investors to investment and governance models in other jurisdictions”, emphasises Paulo Bandeira, partner responsible for the Startup Lab at SRS.